CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Second Filgrastim Biosimilar Gets Thumbs Up From the FDA

Published: Fri, 20 Jul 2018 18:44:29 EDT
The FDA has granted approval to Nivestym, which has several clinical uses.
FDA Approvals

Updated TAVR Consensus Document Highlights Quality, Not Just Volume

Published: Fri, 20 Jul 2018 17:03:36 EDT
The multisociety document lays the groundwork for judging TAVR program performance based on quality of care and volume, while the Centers for Medicare & Medicaid Services is reviewing minimum volume.
Medscape Medical News

HHS May Alter Rebate Rules for PBM Drug Middlemen

Published: Fri, 20 Jul 2018 16:53:21 EDT
The Trump administration appears ready to press for changes in the savings provided to pharmacy benefit managers (PBMs). The president has been an open critic of this industry.
Medscape Medical News
Displaying results 1-3 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Insilico and A2A launch new Duchenne-focused AI drug company

Published: Fri, 20 Jul 2018 19:37:51 +0000
Two artificial intelligence-based drug design firms, Insilico Medicine and A2A Pharmaceuticals, have launched a new joint company aimed at developing small molecules for Duchenne muscular dystrophy and other rare orphan diseases.

PTC inks $200M Agilis takeover to snag late-phase gene therapy

Published: Fri, 20 Jul 2018 10:11:57 +0000
PTC Therapeutics is paying $200 million upfront to acquire Agilis Biotherapeutics. The deal gives PTC ownership of a gene therapy treatment for rare neurotransmitter disease AADC deficiency that is set to go before the FDA next year.

Patient death prompts FDA hold on Mersana’s lead cancer ADC

Published: Fri, 20 Jul 2018 09:38:59 +0000
Another antibody-drug conjugate has been stalled by concerns over safety. The FDA has placed a partial hold on Mersana’s lead candidate XMT-1522 after a patient death in a phase 1 trial, causing its shares to plunge.
Displaying results 1-3 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top